Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria

被引:20
|
作者
Akech, Samuel O. [1 ]
Jemutai, Julie [1 ]
Timbwa, Molline [1 ]
Kivaya, Esther [1 ]
Boga, Mwanamvua [1 ]
Fegan, Greg [1 ,2 ]
Maitland, Kathryn [1 ,3 ,4 ]
机构
[1] Ctr Geog Med Res Coast, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya
[2] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England
[4] Univ London Imperial Coll Sci Technol & Med, Global Hlth Programme, London, England
基金
英国惠康基金;
关键词
clinical trials; child; malaria; acidosis; colloids; Dextran; starch; CLINICAL-PRACTICE PARAMETERS; HYDROXYETHYL STARCH; HEMODYNAMIC SUPPORT; VOLUME EXPANSION; RENAL-FUNCTION; ALBUMIN; MANAGEMENT; RESUSCITATION; INDICATORS; ACIDOSIS;
D O I
10.1097/CCM.0b013e3181e81165
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: A previous meta-analysis has shown a consistent survival benefit in children with severe malaria receiving human albumin solution compared to other resuscitation fluids. Human albumin solution is expensive and not readily available in Africa. We examined the safety and efficacy of the fluid resuscitation with two synthetic colloids, Dextran 70 and hydroxyethyl starch, to inform future trial design. Design: An open-label randomized, controlled, phase II safety and efficacy trial. Setting: High-dependency unit, Kilifi District Hospital, Kenya. Patients: Children aged >6 months with severe falciparum malaria and acidosis (base deficit >8 mmol). Interventions: Boluses (20-40 mL/kg) of 6% Dextran 70 and 6% hydroxyethyl starch (130/0.4). Measurements and Main Results: Primary end point: resolution of shock over 8 hrs. Secondary end points include resolution of acidosis, in-hospital mortality, and adverse events (allergic reactions, pulmonary edema, and neurologic sequelae). A total of 79 children were enrolled: 39 received Dextran 70 and 40 received hydroxyethyl starch. No significant difference was observed in Dextran 70 and hydroxyethyl starch groups for shock resolution at 8 hrs: 23/37 (62%) and 25/39 (64%), respectively (p = .99). Acidosis resolution and respiratory distress were marginally superior in the hydroxyethyl starch group: 3/39 (8%) remained acidotic at 8 hrs versus 10/37 (27%) in the Dextran 70 arm (p = .05). There were four deaths (5%): two per arm, including three deaths in the coma subgroup (3/39, 8%). No other new adverse event was reported. Conclusions: Correction of shock by volume expansion with either Dextran 70 or hydroxyethyl starch in children with severe malaria acidosis is safe with low mortality, including the highest risk cases admitted in coma. Both solutions present an attractive and practical option for consideration in future volume resuscitation trials in severe malaria. (Crit Care Med 2010; 38: 1630-1636)
引用
收藏
页码:1630 / 1636
页数:7
相关论文
共 50 条
  • [31] Does iron therapy benefit children with severe malaria-associated anaemia? A clinical trial with 12 weeks supplementation of oral iron in young children from the Turiani Division, Tanzania
    vandenHombergh, J
    Dalderop, E
    Smit, Y
    JOURNAL OF TROPICAL PEDIATRICS, 1996, 42 (04) : 220 - 227
  • [32] Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID)
    Shaw, Kit L.
    Sokolic, Robert
    Davila, Alejandra
    Silvin, Christopher
    Garabedian, Elizabeth
    de Oliveira, Satiro
    Barman, Provaboti
    Brown, Berkley
    Carbonaro, Denise
    Geiger, Sabine
    Mishra, Suparna
    Smogorzewska, Monika
    Jagadeesh, Jayashree
    Hershfield, Michael S.
    Wayne, Alan
    Crooks, Gay M.
    Moore, Theodore
    Candotti, Fabio
    Kohn, Donald B.
    MOLECULAR THERAPY, 2014, 22 : S107 - S107
  • [33] Phase II Clinical Gene Therapy Trial for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID)
    Shaw, Kit L.
    Sokolic, Robert
    Mishra, Suparna
    de Oliveira, Satiro
    Silvin, Christopher
    Sabine, Geiger-Schredelseker
    Berkley, Brown
    Elizabeth, Garabedian
    Smogorzewska, Monika
    Carbonaro, Denise A.
    Fu, Pei-yu
    Davila, Alejandra
    Jagadeesh, Jayashree
    Hershfield, Michael
    Wayne, Alan
    Kapoor, Neena
    Moore, Theodore
    Candotti, Fabio
    Kohn, Donald B.
    MOLECULAR THERAPY, 2013, 21 : S118 - S118
  • [34] Secukinumab efficacy in moderate to severe psoriasis appears not to be affected by previous biologic use: Results of a phase II, regimen-finding trial
    Lebwohl, Mark
    Elewski, Boni
    Papavassilis, Charis
    Thurston, Helen Jane
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
  • [35] Secukinumab efficacy in moderate to severe psoriasis appears not to be affected by previous biologic use: Results of a phase II, dose-ranging trial
    Leonardi, Craig
    Morita, Akimichi
    Richards, Hanno
    Thurston, Helen Jane
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB211 - AB211
  • [36] Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study
    Bartels, Ute
    Onar-Thomas, Arzu
    Patel, Sunita K.
    Shaw, Dennis
    Fangusaro, Jason
    Dhall, Girish
    Souweidane, Mark
    Bhatia, Aashim
    Embry, Leanne
    Trask, Christine L.
    Murphy, Erin S.
    MacDonald, Shannon
    Wu, Shengjie
    Boyett, James M.
    Leary, Sarah
    Fouladi, Maryam
    Gajjar, Amar
    Khatua, Soumen
    NEURO-ONCOLOGY, 2022, 24 (06) : 974 - 983
  • [37] Phase I/II Trial of Concurrent Use of S-1 and Radiation Therapy for T2 Glottic Cancer
    Nakayama, Meijin
    Hayakawa, Kazushige
    Okamoto, Makito
    Niibe, Yuzuru
    Ishiyama, Hiromichi
    Kotani, Shouko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 921 - 926
  • [38] Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial
    Byakika-Kibwika, Pauline
    Achan, Jane
    Lamorde, Mohammed
    Karera-Gonahasa, Carine
    Kiragga, Agnes N.
    Mayanja-Kizza, Harriet
    Kiwanuka, Noah
    Nsobya, Sam
    Talisuna, Ambrose O.
    Merry, Concepta
    BMC INFECTIOUS DISEASES, 2017, 17
  • [39] Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial
    Pauline Byakika-Kibwika
    Jane Achan
    Mohammed Lamorde
    Carine Karera-Gonahasa
    Agnes N. Kiragga
    Harriet Mayanja-Kizza
    Noah Kiwanuka
    Sam Nsobya
    Ambrose O. Talisuna
    Concepta Merry
    BMC Infectious Diseases, 17
  • [40] Preparation for a Phase I/II Clinical Trial of T Cell Suicide Gene Therapy Following Haematopoietic Stem Cell Transplantation in Children
    Zhan, H.
    Thrasher, A.
    Farzaneh, F.
    Bhalla, J.
    Chan, L.
    Veys, P.
    Fehse, B.
    Gaspar, H.
    Qasim, W.
    HUMAN GENE THERAPY, 2010, 21 (04) : 509 - 509